Accelerating the Next Generation of CNS Therapeutics Through Breakthrough Brain Delivery Technologies
Uniting 100+ global leaders across biopharma, biotech, academia, translational research, drug delivery, DMPK, protein engineering, platform development, investment, and business development, the 8th CNS Drug Delivery Summit is the industry's premier forum dedicated to overcoming one of the greatest challenges in drug development: achieving safe, effective, and scalable delivery to the brain.
Following the landmark FDA approval of Denali's Avlayah, the first therapy to leverage BBB shuttle technology, and encouraging clinical progress from programs such as Roche's Trontinemab, the field has entered a new phase of momentum. Clinical validation of receptor-mediated transcytosis has transformed brain delivery from a promising concept into a rapidly advancing therapeutic reality, driving unprecedented investment, partnerships, and platform innovation across biologics, oligonucleotides, gene therapies, and emerging CNS modalities.
With 25+ expert speakers and a highly technical, cross-functional agenda spanning discovery biology, translational sciences, DMPK, protein engineering, biodistribution, toxicology, clinical development, and investment strategy, attendees will gain actionable insights into the technologies, tools, and translational frameworks shaping the future of CNS drug delivery. The Summit is specifically designed to help teams improve CNS exposure, optimize dose scaling, minimize systemic toxicity, and accelerate the translation of next-generation delivery platforms into clinical success.
![CB-CDx-0107-min-scaled111-1024x681[1]](https://cns-drug-delivery.com/wp-content/uploads/sites/287/2026/02/CB-CDx-0107-min-scaled111-1024x6811-1.jpg "CB-CDx-0107-min-scaled111-1024x681[1]")
Agenda Focus
This year's agenda explores the latest advances in BBB shuttle technologies, novel receptor-mediated transport systems beyond TfR1, oligonucleotide delivery, gene therapy vectors, focused ultrasound-mediated BBB opening, intrathecal and direct-to-brain delivery approaches, and next-generation antibody engineering strategies. Attendees will examine how leading organizations are overcoming the limitations of conventional CNS therapeutics through innovative approaches to transport biologics and advanced modalities into the brain.
Dedicated Technology & Platform Development and Biology & Implementation tracks provide tailored content for both platform developers and translational scientists. Discussions will focus on emerging BBB targets, delivery system engineering, biodistribution analysis, imaging technologies, humanized translational models, PK/PD modelling, dose scaling, target engagement, and toxicological assessment, ensuring attendees can apply learnings directly to active CNS programs.
Industry leaders from Roche, Novartis, AbbVie, Eli Lilly, Alnylam, Bristol Myers Squibb, Lundbeck, Voyager Therapeutics, Biogen, Dyne Therapeutics, Stoke Therapeutics, UCB, Harvard Medical School, Harvard University, JCR Pharmaceuticals and more will share the latest data, lessons learned, and perspectives on the future of brain delivery. Dedicated investment and strategic partnership discussions will also examine the technologies attracting the most attention from pharma business development teams and investors as the field moves toward broader clinical validation.
Together, the Summit delivers the scientific insight, translational expertise, and collaborative opportunities required to unlock a new generation of CNS-targeted therapeutics.
Key Features for 2026
Dedicated Biology & Technology Tracks for Cross-Functional CNS Teams
Tailor your experience with focused content streams covering platform engineering, biologics, antibody shuttles, oligonucleotide delivery, biodistribution, DMPK, translational sciences, and implementation strategies.
Sorry, we couldn't find any posts. Please try a different search.
Expanded Investment Insights: Pharma BD & VC Panel
Explore the catalysts driving investment and partnership activity across BBB shuttles, CNS delivery platforms, gene therapies, and next-generation brain-targeting technologies, while discovering what investors and pharma partners are seeking from upcoming clinical readouts.
Clinical Validation of BBB Shuttles & Emerging Brain Targets
Discover the latest learnings from clinically validated BBB shuttle technologies, novel receptor targets beyond TfR1, and emerging approaches to improve CNS exposure, tissue penetration, and therapeutic efficacy.
8+ New Presenting Organizations
New perspectives spanning next-generation shuttles, glycan-targeting approaches, focused ultrasound, gene therapy delivery, biodistribution analysis, and advanced CNS modeling technologies.
2026 Unmissable Highlights
Beyond Transferrin: Unlocking the Next Generation of BBB Shuttle Technologies
Explore emerging BBB targets beyond TfR1, novel receptor-mediated transcytosis strategies, and next-generation shuttle architectures designed to improve brain exposure, with insights from Roche, Lundbeck, Acumen, Voyager Therapeutics, AbbVie, JCR Pharmaceuticals, and Harvard Medical School
Visualizing Brain Exposure: Advancing Biodistribution, Imaging & Translational Models
Learn how cutting-edge imaging, spatial biology, DMPK, and biodistribution technologies are enabling more precise quantification of CNS exposure and target engagement, featuring leaders from Eli Lilly, Lundbeck, Stoke Therapeutics, Bayer, AbbVie, and Harvard University.
Engineering the Future of CNS Delivery Across Antibodies, Oligos & Gene Therapies
Discover how innovators are optimizing antibody shuttles, oligonucleotide delivery, AAV capsids, RNA conjugates, and next-generation vectors to overcome delivery bottlenecks across neurological diseases, with contributions from Voyager Therapeutics, Stoke Therapeutics, Eli Lilly, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Vianautis.
Systemic vs Direct-to-Brain Delivery: Defining the Optimal Route to the CNS
Examine the advantages, limitations, and clinical realities of BBB-crossing platforms, intrathecal administration, convection-enhanced delivery, implantable devices, and focused ultrasound, with perspectives from AbbVie, Biogen, Eli Lilly, Lotus Neuroscience, and leading neurosurgical experts.
From Preclinical Promise to Clinical Proof: Improving Translation & Dose Scaling
Unpack the challenges of predicting human CNS exposure through advanced BBB models, humanized animal systems, PK/PD modelling, and translational toxicology, with expertise from Stoke Therapeutics, MIT, UCB, Wave Life Sciences, and industry leaders in CNS development.
Where Capital is Flowing: Investment, Deal-Making & Commercialization in CNS Delivery
Hear directly from pharma, biotech, BD leaders, and investors on the technologies attracting investment, partnership activity, and acquisition interest as BBB shuttles and CNS delivery platforms move toward clinical validation, with participation from Daiichi Sankyo, Novartis, Eli Lilly Ventures, and SV Health Investors.
Divide & Conquer
Track 1: Technology & Platform Development
Designed for drug delivery, platform, biologics, antibody, oligonucleotide, vector, protein engineering and chemistry teams developing the next generation of CNS delivery technologies. Explore the engineering, chemistry and design principles underpinning brain shuttles, capsids, conjugates and device-enabled delivery systems to improve BBB transport, brain exposure and delivery efficiency.
Track 2: Biology & Implementation
Designed for neuroscience, biology, pharmacology, DMPK, PKPD and translational development teams seeking to evaluate, implement and de-risk CNS delivery approaches within therapeutic programs. Explore biodistribution, target engagement, in vitro and in vivo models, dose translation, safety assessment and disease-specific case studies to understand how delivery technologies perform in real-world development settings.
Explore the Full Event Guide
- 25+ World Class Speakers with Cutting Edge Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Content Spanning CNS Biology, Platform & Tech, Chemistry, DMPK, BD & More for the Whole Team
![60515-brochure[1]](https://cns-drug-delivery.com/wp-content/uploads/sites/287/2024/08/60515-brochure1.png "60515-brochure[1]")
Attending Companies Include
![CB-CDx-0690-min-scaled111-768x511[1]](https://cns-drug-delivery.com/wp-content/uploads/sites/287/2024/06/CB-CDx-0690-min-scaled111-768x5111-1.jpg "CB-CDx-0690-min-scaled111-768x511[1]")
Explore the Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 25+ expert speakers shaping the future of CNS drug delivery
![Untitled-1280-x-851-px-768x511[1]](https://cns-drug-delivery.com/wp-content/uploads/sites/287/2024/06/Untitled-1280-x-851-px-768x5111-1.png "Untitled-1280-x-851-px-768x511[1]")
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider to CNS drug developers focused on brain delivery
![Untitled-1280-x-851-px-1-768x511[1]](https://cns-drug-delivery.com/wp-content/uploads/sites/287/2024/06/Untitled-1280-x-851-px-1-768x5111-1.png "Untitled-1280-x-851-px-1-768x511[1]")
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and regulatory voices driving real-world adoption